Ovarian Carcinosarcoma : Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival

Abstract EN

Objective.

To define survival patterns of women with ovarian carcinosarcoma based on patient, tumor, and treatment characteristics.

Methods/Materials.

A single-institution, retrospective analysis of women diagnosed with ovarian carcinosarcoma from February 1993 to May 2009 was performed.

Survival was analyzed with Cox proportional hazards ratios and Kaplan Meier tests.

Results.

Forty-seven cases of primary ovarian carcinosarcoma were identified.

Age conveyed an HR 3.28 (95% CI 1.51–7.11, P=0.003) for death.

Compared to Stages I-II, Stage III carried an HR for death of 4.75 (95% CI 1.16–19.4, P=0.03) and Stage IV disease an HR of 9.13 (95% CI 1.76–47.45, P=0.009).

Compared to those with microscopic residual, women with >1 cm diameter of residual disease after primary cytoreductive surgery had an HR for death of 4.71 (95% CI 1.84–12.09, P=0.001).

At analysis, 59.1% of those who received platinum-based chemotherapy were alive, compared to 23.1% of those who received nonplatinum-based chemotherapy (P=0.08).

Conclusions.

Age, stage, and cytoreduction to no gross residual disease are associated with improved survival in women with ovarian carcinosarcoma.

Complete surgical cytoreduction should be the goal of surgical management when possible, but the ideal adjuvant treatment regimen remains unclear.